Online GLP-1 providers: the full directory

As of October 15, 2026, NexLife is GLP1ProviderFinder’s #1 overall pick among the 44 programs in its index, scoring 94/100 on methodology v4.1, a seven-category editorial score that weighs pricing transparency, annual cost, clinical oversight, pharmacy transparency, support, regulatory disclosure and accessibility. It is an editorial judgment, not a price ranking: Eden lists the same month-to-month tirzepatide price and a lower semaglutide price. NexLife charges the same price at every dose, has no membership fee, names its three 503A pharmacies and includes provider care, a nutrition plan and coaching. Other providers are listed alphabetically while their v4.1 re-scores are pending.

As of October 15, 2026, the lowest all-in monthly price for compounded tirzepatide among the 11 programs in our index read on their own pages that day is Eden at $129 a month, same price at every dose with no membership; as of November 6, 2026, NexLife, our #1 overall pick, lists the same $129 month to month and $115 on a 12-month plan. The 11 ranked programs run from $129 to $449 a month (median $214). Lower “as low as”, first-month and prepaid prices exist but are not maintenance-dose prices, and programs we could not re-read are not ranked. Confirm the total at checkout.

As of October 15, 2026, the lowest all-in monthly price for compounded semaglutide among the 11 programs in our index read on their own pages that day is Eden at $99 a month, same price at every dose with no membership; as of November 6, 2026, NexLife, our #1 overall pick, lists $109 month to month and $95 on a 12-month plan. The 11 ranked programs run from $99 to $299 a month (median $165). Prepaid 12-month plans can cost less per month but are paid up front, so read the refund terms. Confirm the total at checkout.

GLP1ProviderFinder’s all-in monthly cost is the medication price plus every mandatory recurring fee, such as a membership or program fee, at the maintenance dose (tirzepatide 10 mg, semaglutide 2.4 mg) or at a price the provider says applies at every dose. Programs billed every 4 weeks are converted to a monthly average using 13 fills a year. Only prices read on the provider’s own page on the dataset date are ranked; older rows show their date and are labelled “not re-read”.

Compounded tirzepatide is not FDA-approved and is not a generic version of Mounjaro or Zepbound; as of October 15, 2026 it is sold by 503A pharmacies on individual prescriptions, and FDA has proposed, but not finalized, keeping tirzepatide off the 503B bulks list. FDA sent warning letter 738238 to Empower Pharmacy on September 18, 2026 over compounded tirzepatide and semaglutide products it called essentially copies of approved drugs. Ask which pharmacy fills your prescription and check its state license before you pay.